TRIM21 restricts coxsackievirus B3 replication, cardiac and pancreatic injury via interacting with MAVS and positively regulating IRF3-mediated type-I interferon production
There is a unique opportunity for collaboration across specialties to raise awareness around the multiple benefits of GLP-1 RAs and determine the best care pathway to treat patients with PAD. With the ongoing PAD amputation and obesity epidemics, there is an opportunity to establish partnership and open communication between vascular surgeons and weight loss clinics to determine if a patient could benefit from GLP-1 RAs
Key insights throughout this article have highlighted the mechanisms of action for both compounds, the potential benefits of their combined use, and the critical importance of safety monitoring
Both contain GLP-1 receptor agonist activity (semaglutide in CagriSema, the GLP-1 component of retatrutide), which would overlap
There is also the ever-present threat of the now infamous Ozempic face, which experts describe as rapid weight loss in the face and loss of skin elasticity, creating an significantly older appearance
It requires a medical evaluation, a BMI of 35 or higher or a BMI of 30-34 with a chronic health condition like heart disease or diabetes,[8] and a mental health screening (some require initial weight loss to prove commitment)
